NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) secured a new Australian patent (No. 2022370513) for its PrimeC fixed‑dose combination of ciprofloxacin and celecoxib, extending the company’s exclusivity in Australia through October 2042. The grant follows a U.S. patent (No. 12,097,185) and a prior Australian patent granted in March 2022 that expired in June 2038, giving PrimeC a continuous, overlapping protection period that strengthens the company’s global IP strategy.
PrimeC is a multi‑targeted therapy under development for amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. The drug is Phase 3‑ready for ALS, having achieved positive Phase 2b results and received FDA clearance for a pivotal Phase 3 protocol. The Australian patent protects the fixed‑dose formulation, which delivers coordinated neuroinflammation, iron dysregulation, and miRNA modulation in a single oral dose.
The patent grant signals regulatory and market confidence in PrimeC’s design and supports NeuroSense’s strategy to secure upfront funding and future royalties from a global partner. By adding Australia—a major market—to its IP portfolio, the company enhances its competitive moat and positions itself for future licensing and commercialization deals in a key jurisdiction.
NeuroSense’s CEO Alon Ben‑Noon emphasized the strategic importance of the grant, stating, “Securing patent protection in Australia, in addition to the already granted patent in the U.S., is an important step in executing our global IP protection strategy for PrimeC. As we advance PrimeC toward pivotal development and potential commercialization, building a broad, durable IP estate across major jurisdictions is central to supporting long‑term value creation.”
The event does not immediately impact cash flow, but it strengthens the strategic value of the pipeline and positions NeuroSense for future licensing and commercialization opportunities in a major market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.